ABSTRAK
INTRODUCTION
In the current pathophysiological model, heart failure is characterized by a constant stimulation of several neurohormonal systems, which are able to restore the cardiac output in early phases of the process, but become inefficient, harmful and responsible for the progression of the myocardial dysfunction in the long term. BNP (Brain Natriuretic Peptide) secreted by left ventricle as response to wall stress in patient with heart failure (Localzo et al 2010) . The plasma concentration of BNP and its fragmen N-terminal pro-brain natriuretic peptide (NT-pro-BNP) is a strong prognostic indicator for patients with heart failure (HF) across all stages of the condition. NT-proBNP is favourable to analysis because of longer half live and stability in sample (Mueller 2004) .
Several clinical trials have demonstrated convincingly that neurohormonal modulation on the renin angiotensin aldosterone system (RAAS) decreases plasma NTproBNP level and results in favorable outcomes. One of the drug used for blocked RAAS system is ACE inhibitor. ACE inhibitor reduce intravascular volume, cardiac filling pressure, prevent remodelling in long term and the consequences reduce level of NT-proBNP. Decrease of NT-proBNP level show response to therapy include therapy with ACE inhibitors (Tsutamoto et al 2008) . Still limited data for the effect of ACE inhibitor for the changes of neurohormonal activity in patients with heart failure.The natriuretic peptides have been the most frequently recommended measurement, given their good correlation with the severity of ventricular dysfunction and the consistent methodology for their analyses (Kim & Januzzi 2011 ).
The primary objective of this study was to to analize changes in the levels plasma nt-probnp levels after ace inhibitor therapy in patients with heart failure. Secondarily, to monitoring creatinine serum in patient with ACE inhibitors therapy for two months observ-ation.
MATERIALS AND METHODS
This study was a prospective, non-randomized trial conducted in cardiovascular ambulatory patient dr. Soetomo hospital Surabaya involving patient with age 21-75 years with heart failure NYHA class II, using ACE inhibitor therapy plus standard therapy maximum 3 months before study without disease. ARB or beta blocker and willing to follow this study by signing informed cosent We compared plasma NT-pro-BNP and creatinine serum parameters before and after two months treatment with ACE inhibitor. Patient which has creatinine serum > 2 mg/dL and BMI > 30 kg/m2 were excluded from the study.
Blood sample collected from all patient at baseline and two months after received ACE inhibitors therapy in order to analyze serum NT-proBNP and creatinine serum. The blood collected for serum NT-proBNP measurement was centrifuged and kept at -freezer until the time of the measurement. The sample were storage at 2-8oC freezer. The concentration serum NT-proBNP was measured by IMMULITE® 1000 Turbo device. In this study we used human NT-proBNP CLIA kit from IMMULITE. We performed the analysis in laboratorium clinical pathology, diagnostic center building dr. Soetomo hospital Surabaya. Descriptive analyses were performed to determine the demographic, characteristic patient, and profile Nt-proBP and creatinine serum at baseline and post therapy two months. Changes in level NT-proBNP was measured by SPSS software using paired t-test methods. A p value<0.05 was regarded as significant.
RESULT
During the study period, 15 consecutive patient with heart failure were screened for eligibility. Of these, 13 were eligible. Baseline characteristic on admission are shown in table 1. Mostly patient age was 55-74 years and included 7 man and 6 woman. The most common cuse of heart failure in patients are old miokard infark (46.2%), 2 patient had AF and PHT as complication. All patient had DCFC NYHA class II. Serum NT-proBNP levels ranged from 486 to 5243 pg/ml at baseline. The average NT-proBNP value at baseline was 2166.92±1236,735 pg/ml. In the comparisons between two months, we observed a mean reduction by 803.5 pg/ml or 26.7% in relation to baseline. In post therapy two months serum NT-proBNP levels was 477 to 3525 pg/ml. The Average NT-proBNP levels at post two months 1508.23±651,094 pg/ml. Decreased of NT-proBNP after two months occurs in 12 from 13 patient. One patient had increased Nt-proBNP levels from baseline. The levels of NT-proBNP baseline or pre therapy and post therapy of each patient shown in figure  1 . There was significantly changes between NT-proBNP pre and after post two months therapy (p=0.025; figure   2 ) with ACE inhibitors in patients with heart failure. The secondary parameter was creatinin serum. There was no significantly diffrences between creatinine serum pre and post two months therapy with ACE inhibitors in patients with heart failure. The mean of % changes in NT-proBNP level were 26.7%. In the result of this study we divide NT-proBNP levels in patient into several category. First category was NT-proBNP below 1000 pg/ml and above 1000 pg/ml in pre and post therapy. Second category was changes of NT-proBNP levels at post more than 25% and changes less than < 25% (table 2) . 1000 pg/ml was the cut off value for NT-proBNP in patient with chronic condition The result show 23.1% patient reached cut off target NT-proBNP levels. Changes NT-proBNP more than 25% (decrease or increase) show clinical significance. In this study 38.5% patient reached clinical significant changes. We also calculate the glomerulus filtration rate from creatinine serum of each patient with cocroft and gault methods and divide the GFR of patient into GFR above 60 ml/minute and below 60 ml/minute (table 2) .
DISCUSSION
ACE inhibitors reduce intravascular plasma volume, ventricular filling pressure, and, consequently, NTproBNP levels. In the treatment of HF, reductions in NT-proBNP concentrations, when detected by sequential analyses of the same patient, are correlated with improved symptoms, increased functional capacity, reduced rate of clinical endpoints and better prognosis. On the other hand, persistently elevated NT-proBNP levels despite treatment identify patients with worse prognosis (Neto 2008) . Our result showed the beneficial effect of ACE inhibitor on reducing NT-proBNP levels as cardiac stress marker. By the end of two months, mean change of NT-proBNP level were 26.7% from baseline, with statistically significant reduction in all comparison. ACE inhibitor used in this study were ramipril, lisinopril and captopril and the dose use suited by patient condition. Patient tolerate well with therapy given, so during two months patient get stabil dose, no change or addition therapy such as ARB and beta bloker. In this study 9 patient use spironolacton which could reduce NT-proBNP level in long therm therapy (Tsutamoto 2001) .
Cut off value below 1000 pg/ml in prior study showed significantly low risk of bad prognosis and outcome, whereas subjects with NT-proBNP concentrations above 1000 pg/ml showed high risk (Januzzi 2011) .
Beside cut off value, we could assess serial NT-proBNP levels from % change from baseline. Because of analytic imprecision and biological variation, NT-pro-BNP changes >25% from baseline correlate well with clinical course in follow-up of patients with heart failure (Morrow 2006) . In this study, we found more patient not reached target cut off value < 1000 pg/ml and the decrease NT-proBNP levels still > 25% might be due observation time (two month) was not long enough. In several study before, the follow up time between 4-6 month.
In this study we found one patient experience increased NT-proBNP levels. Even though the patient looked stable, those with NT-proBNP increase >25% from baseline, associated with increased risk in hospitalisation and mortality. Consider for drug therapy intensification and/or careful reassessment of their medical programs irrespective of clinical status or perception of the presence of an optimal medical program (Januzzi 2011) . Secondary parameter in this study was creatinin serum. Measurement the value of serum creatinine continuosly in patients receiving ACE inhibitor therapy is recommended to monitor the patient's renal function (de Boer & van Veldhuisen 2008) . In this study, the SCr patient in pre and post therapy were in the normal range (0.6-1.3 mg/dl) and there is no significant difrences between SCr levels. Decrease of renal function < 40 ml/ minute could increase NT-proBNP levels because of decreased clearance (Srisawasdi et al 2010 , Tsutamoto 2006 ). So we calculate each patient GFR, and the result patient in this study did not had severe renal failure that could affect NT-proBNP levels.
Study limitations. limitations of our study include that it was relatively small sample size. We couldn't exclude patient with spironolactone because of limited sample and that's might affect the result of this study. Vary between type and dose of ACE inhibitor used in this study and correlation with decreased of NT-proBNP levels need further study. A further study with a larger sample size, longer follow up time and controlled confounding condition suggested in order to get more representatif result.
CONCLUSION
The results in 13 patient demonstrated the benefits of ACE inhibitor on the neurohormonal profile in patients with HF. If necessary we could measure NT-proBNP level to support prognosis data and monitoring effectiv-ity therapy especially ACE inhibitor which had antiremodelling effect towards patients with HF.
